Cargando…

Early Clinical Experiences of Esketamine Nasal Spray in the UK in Adults with Treatment-Resistant Major Depressive Disorder: Advisory Panel Recommendations

PURPOSE: Treatment-resistant depression (TRD) is associated with profound morbidity for patients, placing a significant burden on those affected, the health service and wider society. Despite this, TRD remains chronically underserved in terms of viable treatment options. To address this gap, an advi...

Descripción completa

Detalles Bibliográficos
Autores principales: Young, Allan H, Abdelghani, Mohamed, Juruena, Mario F, Nikolova, Viktoriya L, Nilforooshan, Ramin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9968662/
https://www.ncbi.nlm.nih.gov/pubmed/36861011
http://dx.doi.org/10.2147/NDT.S388392
_version_ 1784897547738808320
author Young, Allan H
Abdelghani, Mohamed
Juruena, Mario F
Nikolova, Viktoriya L
Nilforooshan, Ramin
author_facet Young, Allan H
Abdelghani, Mohamed
Juruena, Mario F
Nikolova, Viktoriya L
Nilforooshan, Ramin
author_sort Young, Allan H
collection PubMed
description PURPOSE: Treatment-resistant depression (TRD) is associated with profound morbidity for patients, placing a significant burden on those affected, the health service and wider society. Despite this, TRD remains chronically underserved in terms of viable treatment options. To address this gap, an advisory panel of psychiatrists and clinical researchers with experience in managing TRD convened to develop best practice statements on the use of esketamine nasal spray, one of the first TRD treatments to be licensed in 30 years. METHODS: During a virtual meeting held on 12th November 2020, the advisory panel shared their experiences of using esketamine nasal spray in their clinical practice. The meeting focused on developing and refining recommendations for setting up and running an efficient esketamine nasal spray clinic for patients living with TRD. At the conclusion of the meeting, agreement was reached on all recommendation statements. RESULTS: In setting up an esketamine nasal spray clinic, it is important to consider the logistical requirements involved and put measures in place to ensure it runs as efficiently as possible. Educating patients about the treatment and maintaining their well-being is paramount for preventing discontinuation. Putting in place checklists can be a useful strategy for ensuring treatment appointments run smoothly and safely. CONCLUSION: Providing additional treatment options for the management of TRD, such as esketamine nasal spray, is likely to be key to improving the long-term outcomes of this underserved patient population.
format Online
Article
Text
id pubmed-9968662
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-99686622023-02-28 Early Clinical Experiences of Esketamine Nasal Spray in the UK in Adults with Treatment-Resistant Major Depressive Disorder: Advisory Panel Recommendations Young, Allan H Abdelghani, Mohamed Juruena, Mario F Nikolova, Viktoriya L Nilforooshan, Ramin Neuropsychiatr Dis Treat Commentary PURPOSE: Treatment-resistant depression (TRD) is associated with profound morbidity for patients, placing a significant burden on those affected, the health service and wider society. Despite this, TRD remains chronically underserved in terms of viable treatment options. To address this gap, an advisory panel of psychiatrists and clinical researchers with experience in managing TRD convened to develop best practice statements on the use of esketamine nasal spray, one of the first TRD treatments to be licensed in 30 years. METHODS: During a virtual meeting held on 12th November 2020, the advisory panel shared their experiences of using esketamine nasal spray in their clinical practice. The meeting focused on developing and refining recommendations for setting up and running an efficient esketamine nasal spray clinic for patients living with TRD. At the conclusion of the meeting, agreement was reached on all recommendation statements. RESULTS: In setting up an esketamine nasal spray clinic, it is important to consider the logistical requirements involved and put measures in place to ensure it runs as efficiently as possible. Educating patients about the treatment and maintaining their well-being is paramount for preventing discontinuation. Putting in place checklists can be a useful strategy for ensuring treatment appointments run smoothly and safely. CONCLUSION: Providing additional treatment options for the management of TRD, such as esketamine nasal spray, is likely to be key to improving the long-term outcomes of this underserved patient population. Dove 2023-02-24 /pmc/articles/PMC9968662/ /pubmed/36861011 http://dx.doi.org/10.2147/NDT.S388392 Text en © 2023 Young et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Commentary
Young, Allan H
Abdelghani, Mohamed
Juruena, Mario F
Nikolova, Viktoriya L
Nilforooshan, Ramin
Early Clinical Experiences of Esketamine Nasal Spray in the UK in Adults with Treatment-Resistant Major Depressive Disorder: Advisory Panel Recommendations
title Early Clinical Experiences of Esketamine Nasal Spray in the UK in Adults with Treatment-Resistant Major Depressive Disorder: Advisory Panel Recommendations
title_full Early Clinical Experiences of Esketamine Nasal Spray in the UK in Adults with Treatment-Resistant Major Depressive Disorder: Advisory Panel Recommendations
title_fullStr Early Clinical Experiences of Esketamine Nasal Spray in the UK in Adults with Treatment-Resistant Major Depressive Disorder: Advisory Panel Recommendations
title_full_unstemmed Early Clinical Experiences of Esketamine Nasal Spray in the UK in Adults with Treatment-Resistant Major Depressive Disorder: Advisory Panel Recommendations
title_short Early Clinical Experiences of Esketamine Nasal Spray in the UK in Adults with Treatment-Resistant Major Depressive Disorder: Advisory Panel Recommendations
title_sort early clinical experiences of esketamine nasal spray in the uk in adults with treatment-resistant major depressive disorder: advisory panel recommendations
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9968662/
https://www.ncbi.nlm.nih.gov/pubmed/36861011
http://dx.doi.org/10.2147/NDT.S388392
work_keys_str_mv AT youngallanh earlyclinicalexperiencesofesketaminenasalsprayintheukinadultswithtreatmentresistantmajordepressivedisorderadvisorypanelrecommendations
AT abdelghanimohamed earlyclinicalexperiencesofesketaminenasalsprayintheukinadultswithtreatmentresistantmajordepressivedisorderadvisorypanelrecommendations
AT juruenamariof earlyclinicalexperiencesofesketaminenasalsprayintheukinadultswithtreatmentresistantmajordepressivedisorderadvisorypanelrecommendations
AT nikolovaviktoriyal earlyclinicalexperiencesofesketaminenasalsprayintheukinadultswithtreatmentresistantmajordepressivedisorderadvisorypanelrecommendations
AT nilforooshanramin earlyclinicalexperiencesofesketaminenasalsprayintheukinadultswithtreatmentresistantmajordepressivedisorderadvisorypanelrecommendations